Morgan Stanley Initiates Coverage on Generate Biomedicines (NASDAQ:GENB)

Research analysts at Morgan Stanley started coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a research note issued to investors on Tuesday. The firm set an “overweight” rating and a $20.00 price target on the stock. Morgan Stanley’s price target points to a potential upside of 59.74% from the stock’s current price.

A number of other analysts also recently issued reports on the company. The Goldman Sachs Group assumed coverage on Generate Biomedicines in a research report on Tuesday. They issued a “buy” rating and a $26.00 price target for the company. Wall Street Zen upgraded shares of Generate Biomedicines to a “hold” rating in a research report on Saturday, March 14th. Guggenheim assumed coverage on shares of Generate Biomedicines in a report on Tuesday. They issued a “buy” rating and a $30.00 target price for the company. Finally, Cantor Fitzgerald started coverage on shares of Generate Biomedicines in a research note on Tuesday. They set an “overweight” rating for the company. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Generate Biomedicines presently has an average rating of “Buy” and a consensus target price of $25.00.

Generate Biomedicines Stock Performance

NASDAQ:GENB opened at $12.52 on Tuesday. Generate Biomedicines has a 1 year low of $11.00 and a 1 year high of $15.32.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.